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Objective: It has been proposed that patients whose conditions do not meet North American Symptomatic Carotid
Endarterectomy Trial inclusion criteria or have anatomic risk factors constitute a “high-risk” group for carotid
endarterectomy (CEA) and might be candidates for primary carotid angioplasty stenting. Our objective was to review a
consecutive series of isolated CEAs, identify the number of such patients at high risk, and determine whether their
operations were associated with increased complication rate.
Methods: Consecutive isolated CEAs performed between June 1996 and June 2001 were reviewed. High-risk comorbidi-
ties included: age 80 years or more (n  80), New York Heart Association class III/IV angina (n  16), Canadian class
III/IV heart failure (n  4), myocardial infarct 6 months or less (n  11), steroid-dependent or oxygen-dependent
pulmonary disease (n  4), and creatinine level of 3 or more (n  13). Anatomic high risk was defined by: contralateral
occlusion (n  66), lesion above C2 or requirement of digastric division (n  53), reoperation (n  29), and neck
radiation (n  3). Statistical analysis was with 2 analysis.
Results: Of 788 patients reviewed, 228 (29%) were classified as high risk by one or more of the previous criteria (63%
comorbidity, 28% anatomy, 9% both). Presence of preoperative neurologic symptoms and postoperative results were
similar across all patient groups. The total stroke and death rate was 1.1% for all the patients. Six patients had
postoperative strokes (0.8%), and three patients died of myocardial infarcts (0.4%). The stroke and death rate was 1.3%
in the high-risk group as compared with 1.1% in the normal-risk group (P  .51).
Conclusion: The concept of the high-risk CEA must be critically reexamined. Although 29% of patients for CEA were high
risk as defined by others, we found no evidence that this influenced the results after CEA. Patients with significant medical
comorbidities, contralateral carotid occlusion, and high carotid lesions can undergo operation without increased
complications. If a high-risk group exists, it is small and restricted to reoperation or radiated neck (4% in this series). With
this possible exception, carotid angioplasty stenting should be restricted to randomized clinical trials. (J Vasc Surg 2003;
37:40-6.)
Cerebrovascular accident (CVA) is the third leading
cause of death in the United States after heart disease and
cancer.1 In the United States, more than 500,000 new
CVAs occur annually, and the incidence rate rises exponen-
tially with advancing age.2 A significant portion of these
CVAs is caused by emboli arising from the extracranial
carotid arteries.
Carotid endarterectomy (CEA) has been shown by
several randomized prospective studies3,4 to be safe and
effective in significantly reducing the incidence of stroke in
patients with symptomatic and asymptomatic extracranial
carotid disease. In the current era of minimally invasive
technology, carotid angioplasty stenting (CAS) has
emerged and been explored as a potential alternative to the
standard of care. Despite the fact that several early random-
ized studies were unsuccessful in establishing the benefits of
CAS, proponents of this new technology have recom-
mended the application of CAS in a subset of patients who
are considered to be at “high risk” to undergo CEA.
The definition of patients at high risk varies among
authors. Many include patients excluded from previous
randomized trials3,4 (ie, age 80 years, medical high risk,
contralateral occlusion, prior CEA). This would represent a
20% to 30% cohort of a contemporary carotid practice.5,6
No data exist that clearly define any large group of patients
at increased risk for complication after CEA. In an effort to
determine whether this cohort accurately represents a
group at increased risk to undergo CEA, we retrospectively
reviewed our institutional experience of a contemporary
series of isolated CEAs, identified the proportion of pa-
tients included as high risk in the published literature, and
evaluated their outcome.
METHODS
During a 5-year period from June 1, 1996, to June 1,
2001, 788 consecutive isolated CEAs were performed at
SUNY Stony Brook University Hospital and Winthrop
University Hospital. Office charts and hospital records were
retrospectively reviewed, and the data were used to classify
these patients into either a normal-risk or high-risk group.
The high-risk factors included physiologic risk and ana-
tomic risk factors (Table I).
The physiologic risk factors included: 1, age 80 years or
more; 2, recent myocardial infarct (6 months); 3, New
York Heart Association functional class III or IV; 4, Cana-
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dian Cardiovascular Association heart failure functional
class III or IV; 5, severe pulmonary dysfunction defined as
steroid or oxygen dependent; and 6, severe renal dysfunc-
tion defined as serum creatinine level of 3 or more. The
anatomic risk factors included: 1, contralateral occlusion; 2,
anatomically limited access defined by a lesion above C2 on
angiography or requirement of division of digastric muscle;
3, previous ipsilateral CEA; and 4, postradiation treatment
stenosis. A patient was classified as high risk if one or more
of the previous risk factors were identified, and each patient
could be classified in more than one category.
Indication for CEA included the presence of a hemo-
dynamically significant (50% diameter reduction) carotid
stenosis in a symptomatic patient. Patients without symp-
toms who had high-grade carotid stenosis (70% diameter
reduction) were also considered for CEA.
Myocardial infarction (MI), transient ischemic attack,
stroke, and death were identified as primary events in both
the normal-risk and the high-risk groups. MI was defined as
a new Q wave on postoperative electrocardiogram or ele-
vation of cardiac enzymes. Although routine evaluation for
MI was not obtained after CEA in all patients, electrocar-
diogram and cardiac enzymes were evaluated whenever
there was clinically suspicion of cardiac ischemia. There-
fore, although some “silent MIs” may have been missed,
they were not likely to be clinically relevant. Transient
ischemic attack was defined as a new neurologic deficit that
resolved within 24 hours, and stroke was defined as a new
or progression of a neurologic deficit that lasted beyond 24
hours. Other comorbidities (ie, hematoma, cranial nerve
injury) were not analyzed because we believe these results
are not accurate in a retrospective chart review. Statistical
analysis was performed with SPSS software (Corte Madera,
Calif). Comparison of event rates between the two groups
was made with 2 analysis with use of a two-tailed Fisher
exact test when appropriate. A P value of less than .05 was
considered significant.
RESULTS
The patient characteristics in the two groups are out-
lined in Table II. Most patients in each group were white
men with a history of tobacco use and hypertension. Symp-
tomatic carotid disease was the operative indication in 38%
of the normal-risk group and 43% of the high-risk group
(P  .182).
CEA was performed solely on the basis of noninvasive
carotid duplex scan imaging results in 58% of the patients.
An additional diagnostic method was obtained in 42% of
the patients (30% magnetic resonance angiography, 12%
cerebral angiography).
Overall, 228 patients (29%) were classified as high risk
on the basis of the previous criteria. The presence of a
physiologic risk factor accounted for high-risk classification
in 63% and an anatomic factor in 28% of the group. Nine
percent of the patients in the high-risk group had both
physiologic and anatomic components (Fig 1).
The operative characteristics in the two groups were
similar (Table III). A patch was used for closure in 86% of
the patients in the normal-risk group and 84% in the
high-risk group. Most patients in both groups underwent
general anesthesia and had a shunt placed during the pro-
cedure.
The 30-day rate of stroke and death was 1.1% in the
entire group. There were a total of three deaths in the entire
group, all of which were from a MI (none were patients at
medical high risk). The event rates among the patients who
met criteria of high risk were not statistically significant
from the event rates in the normal-risk group (Fig 2).
DISCUSSION
CEA is a firmly established procedure that underwent a
long period of scrutiny before randomized prospective
studies3,4 solidified its role in extracranial carotid occlusive
disease. CAS, on the other hand, is an advancing technol-
ogy in its infancy with many promises. Early randomized
trials7-9 of CAS have either been associated with a high
complication rate or been suspended. Although there have
been several changes in stent technology since these trials
(ie, lower profile devices, embolic protection devices) that
have provided improved results in individual published
series, data on CAS remain anecdotal.10,11 Ongoing ran-
domized prospective clinical trials12 are underway to pro-
vide answers regarding the future role of CAS. Until these
results are available, proponents of this new technology
have recommended the application of CAS in a subgroup of
patients that they consider high risk for CEA. The compo-
sition of this group and its relative size remain uncertain at
present.
On the basis of conclusions of a multidisciplinary panel
at a recent Montefiore Vascular Symposium,13 five indica-
tions were proposed for CAS in patients needing treatment
Table I. High-risk physiologic and anatomic factors
Physiologic risk factors No. Anatomic risk factors No.
Age (y) 80 Contralateral occlusion 66
MI 6 months 11 Reoperation 29
NYHA class III/IV angina 16 Neck radiation 3
Canadian class III/IV CHF 4 High lesion 53
Steroid/oxygen COPD 4
Creatinine level 3 13
NYHA, New York Heart Association; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease.
Table II. Patient characteristics in normal-risk and high-
risk groups
Patient characteristics
Normal-risk group
(n  560)
High-risk group
(n  228)
Male gender 308 (55%) 143 (63%)
White 532 (95%) 225 (98%)
Tobacco use 411 (73%) 171 (80%)
Hypertension 451 (80%) 174 (76%)
Symptomatic 212 (38%) 98 (43%)
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of carotid bifurcation disease. These were: 1, high-risk
status with symptoms; 2, recurrent stenosis; 3, previous
radical neck dissection or cervical irradiation; 4, high bifur-
cation; and 5, indication for CEA in patient unfit for
surgery. The terms high risk, high bifurcation, and unfit
patient were not specifically defined. As a result, many
proponents of CAS have used North American Symptom-
atic Carotid Endarterectomy Trial/Asymptomatic Carotid
Atherosclerosis Study exclusion as their definition of a
patient at high risk unfit for CEA and therefore a candidate
for CAS. The purpose of this study was to review a contem-
porary carotid series of isolated CEAs, identify this high-
risk subgroup as defined by others,5,6,14,15 and determine
whether there was truly an increased incidence rate of
complications in this cohort.
The high-risk factors that have been mentioned include
physiologic and anatomic components. Sixty-three percent
(143/228) of the patients at high risk were identified as
such exclusively on the basis of physiologic factors. We did
not find these patients to have a significantly higher com-
plication rate (stroke and death rate of 1.3% versus 1.1%),
and therefore, we believe they should not be precluded
from undergoing CEA, a procedure with low physiologic
stress. The option of a regional anesthetic for patients
whose conditions are unfit for general anesthesia (ie, severe
pulmonary dysfunction, severe coronary disease) has been
shown to be a reasonable alternative.16
The cost/benefit ratio of CEA in the octogenarian
population has been a controversial topic in the literature.
This is a group that was excluded from previous clinical
trials3,4 by the study designers who thought the risk/
benefit ratio would have a less favorable relationship as
patients became older. Proponents of CAS have suggested
these patients would be better served with a minimally
invasive procedure because of a presumed increased risk of
postoperative complications. However, in a recent article,
Roubin et al17 performed a 5-year prospective analysis on
the immediate and late clinical outcomes of CAS and
reported that in the subgroup of patients aged 80 years or
older, the periprocedural complication rate was an alarming
16%. This is four times higher than a recently reported
series18 of more than 1000 octogenarians undergoing CEA
(stroke and death rate of 3.6%). This higher complication
rate of CAS in octogenarians may be attributed to increased
incidence rate of periprocedural hypotension/bradycar-
dia19 or higher atherosclerotic load of the aortic arch in this
group.20 Thus, it appears that if octogenarians constitute a
high-risk group for CEA, their risk from CAS may be even
higher. Roubin et al17 go on to suggest that the use of distal
protection devices may improve periprocedural outcomes
in this group; however, this remains speculative. At this
time, CAS is not indicated in the very elderly outside
clinical trials.
Patients with severe cardiac comorbidities may repre-
sent a high-risk group. In our series, the proportion of such
patients is small (31/788). In a large part, this is a result of
our tendency to screen patients for CEA, especially those
with asymptomatic stenosis, for coronary artery disease.
Patients who need both CEA and coronary revasculariza-
tion are usually offered combined surgery. Patients who are
neurologically asymptomatic and unfit for coronary surgery
are observed. With this management algorithm, the actual
proportion of high risk from cardiac disease is small (3.9%).
Patients who are treated with combined carotid and
coronary intervention (CEA/coronary artery bypass graft-
ing [CABG]) are a high-risk group that has been looked at
as candidates for CAS. We believed including this group of
patients into our study was not appropriate. These patients
have been shown to have severe atherosclerotic burden, not
only of the coronary and carotid system but also the aortic
arch,20 and should be evaluated separately. Two large stud-
ies5,6 on high-risk CEA included patients undergoing com-
bined CEA/CABG. Clearly, the morbidity and mortality
rates of patients needing two simultaneous operations can-
not be expected to be equivalent to those of CEA alone.
Adding combined surgery to high-risk CEA unfairly in-
creases complication rates in the CEA group. No prospec-
tive series of carotid stenting before CABG have been
reported. The role CAS in patients who need CABG can
only be answered with a prospective study comparing
CEA/CABG with CAS followed by CABG.
Anatomic risk factors included contralateral carotid
occlusion, a high bifurcation, reoperation, and postradia-
tion stenosis. The major support for increased morbidity of
patients with contralateral occlusion comes from post hoc
Fig 1. Distribution for high-risk classification on basis of physiol-
ogy and anatomy.
Table III. Operative characteristics in normal-risk and
high-risk groups
Operative
characteristics
Normal-risk
(n  560)
High-risk
(n  228)
Primary closure 77 (14%) 38 (16%)
Patch closure
Vein 257 (46%) 118 (52%)
Synthetic 226 (40%) 72 (32%)
Shunt
Yes 521 (93%) 222 (97%)
No 39 (7%) 6 (3%)
Anesthesia
General 552 (98%) 224 (98%)
Local 8 (2%) 4 (2%)
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analysis of the North American Symptomatic Carotid End-
arterectomy Trial data.21 In these data, the relation of
shunt use and stroke in patients with contralateral occlusion
was not reported. The conclusion that the presence of a
contralateral carotid occlusion increases stroke risk cannot
be supported by our data and is at best speculative. There
were a total of 66 patients with contralateral occlusion in
our series, with no incidence of stroke or mortality. Recent
reviews have shown that both indications for CEA and
complication rates in this subset of patients should not
differ from the rest of the population. In fact, Mattos et
al,22 in a study of 478 patients (66 of whom had contralat-
eral carotid artery occlusion), showed a perioperative stroke
rate of 3% in patients with an occluded contralateral carotid
artery versus 2.9% in patients with a patent contralateral
carotid artery. Similarly, they found no differences in the
late stroke rates of patients undergoing CEA with an oc-
cluded versus patent contralateral carotid artery. Mackey,
O’Donnell, and Callow23 reported similar results in 670
patients undergoing CEA, 63 of whom had contralateral
carotid occlusion. Their perioperative stroke rate of 5% in
patients with an occluded ICA was similar to the control
group (3%), and there was no difference in late stroke rates.
It is likely that liberal use of intraoperative shunts minimizes
the morbidity of contralateral occlusion.
The incidence of a high bifurcation and its association
with increased stroke rate is poorly described in the litera-
ture. Our definition of high lesion was based on angio-
graphic criteria or, in most patients, review of the operative
report. We recognize this is a subjective characterization.
Nonetheless, our conclusion that high lesions rarely appear
to make CEA more complicated is validated by our data.
We acknowledge that there are some lesions that cannot be
addressed with standard CEA techniques; however, they
are exceedingly rare. In no case were we forced to abandon
CEA because of cephalad extension of disease. In our series,
53 patients (6.7%) were found to have a high bifurcation,
16 patients on the basis of the presence of a lesion above C2
on cerebral angiogram and 37 on the basis of required
division of the digastric muscle to obtain distal exposure of
the internal carotid artery for a satisfactory endarterectomy.
Our experience parallels that of Hans, Shah, and Hans24
and Hobson et al25 who found high lesions in 4% and 1% of
patients, respectively. As in those series,24,25 we did not
find an increased incidence rate of stroke or death (0/53) in
patients with a high bifurcation.
The incidence rate of recurrent stenosis after CEA has
been estimated between 6% and 18%.26,27 Reoperation has
been reported with an increased risk by some authors,28,29
and other more contemporary series30,31 have achieved
morbidity rates that approach those of primary operation.
We have previously reported26 that most recurrent lesions
remain asymptomatic for 3 to 5 years. We believe that
asymptomatic recurrent carotid stenosis must be managed
on a case-by-case basis, with attention to the location and
cause of the lesion and the status of the contralateral carotid
Fig 2. Rate of perioperative event in normal-risk and high-risk groups. TIA, Transient ischemic attack.
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artery. Routine repair of unilateral asymptomatic fibrous
restenosis, with CEA or CAS, is a matter of continued
controversy. Most patients who have multiple medical co-
morbidities or have a limited life expectancy will remain
asymptomatic and could be observed, and patients at good
risk who have a significant life expectancy could be consid-
ered for repair. With this algorithm, we have performed 29
redo CEAs over the last 5 years with no stroke or death in
this group.
Postradiation carotid stenosis is even a more rare indi-
cation for CEA in most series; approximately 100 patients
with carotid disease that occurred after neck irradiation
have been described in the literature, and most have been
isolated case reports. The largest reported series comes
from Kashyap, Moore, and Quinones-Baldrich,32 with 24
patients undergoing 26 carotid artery operations. No
strokes or deaths occurred within 30 days, and six patients
had temporary cranial nerve injuries. Friedell et al33 re-
ported on 10 patients who underwent 11 procedures for
carotid stenosis after neck radiation with no complications.
In our series, only three patients underwent CEA for pos-
tradiation stenosis and no complication was encountered.
Our data are insufficient to comment on the role of CAS in
patients with neck irradiation. These two groups of patients
(reoperation and radiation-induced stenosis) are the only
ones that can be defined before surgery and have been
shown by some authors to have an increased morbidity after
CEA. Although CAS may better serve these patients, the
absolute number of such patients is small.
The concept of the high-risk CEA must be critically
reexamined. Although 29% of patients for CEA were high
risk as defined by others, we found no evidence that this
influenced the results after CEA. Patients with significant
medical comorbidities, contralateral carotid occlusion, and
high carotid lesions can undergo operation without in-
creased complications. If a high-risk group exists, it is small
and restricted to reoperation or radiated neck (4% in this
series). With this possible exception, CAS should be re-
stricted to randomized clinical trials.
REFERENCES
1. Wolf PA, Cobb JL, D’Agostino RB. Epidemiology of stroke. In: Bar-
nett HJ, Stein BM, Mohr JP, Yatsu FM, editors. Stroke: pathophysiol-
ogy, diagnosis, and management. New York (NY): Churchill Living-
ston; 1992. p. 3-27.
2. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occur-
rence of total (first-ever and recurrent) stroke. Stroke 1999;30:2523-8.
3. North American Symptomatic Carotid Endarterectomy Trial Collabo-
rators. Beneficial effect of carotid endarterectomy in symptomatic pa-
tients with high-grade carotid stenosis. N Engl J Med 1991;325:445-
53.
4. Executive Committee for the Asymptomatic Carotid Atherosclerosis
Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA
1995;273:1421-8.
5. Ouriel K, Hertzer NR, Beven EG, O’Hara PJ, Krajewski LP, Clair DG,
et al. Preprocedural risk stratification: identifying an appropriate popu-
lation for carotid stenting. J Vasc Surg 2001;33:728-32.
6. Jordan WD, Alcocer F, Wirthlin DJ, Fisher WS, Warren JA, McDowell
HA, et al. High-risk carotid endarterectomy: challenges for carotid stent
protocols. J Vasc Surg 2002;35:16-22.
7. Alberts MJ. Results of a multicenter prospective randomized trial of
carotid artery stenting vs carotid endarterectomy. Stroke 2001;32:
325d.
8. CAVATAS Investigators. Endovascular versus surgical treatment in
patients with carotid stenosis in the Carotid and Vertebral Artery
Transluminal Angioplasty Study (CAVATAS): a randomized trial. Lan-
cet 2001;357:1729-37.
9. Naylor AR, Bolia A, Abbott RJ, Pye IF, Smith J, Lennard N, et al.
Randomized study of carotid angioplasty and stenting versus carotid
endarterectomy: a stopped trial. J Vasc Surg 1998;28:326-34.
10. Henry M, Henry I, Klonaris C, Masson I, Hugel M, Tzvetanov K, et al.
Benefits of cerebral protection during carotid stenting with the Percu-
Surge GuardWire system: midterm results. J Endovasc Ther 2002;9:1-
13.
11. Whitlow PL, Lylyk P, Londero H, Mendiz OA, Mathias K, Jaeger H, et
al. Carotid artery stenting protected with an emboli containment sys-
tem. Stroke 2002;33:1308-14.
12. Hobson R, Brott T, Ferguson R, Roubin G, Moore W, Kuntz R, et al.
CREST: carotid revascularization endarterectomy versus stent trial.
Cardiovasc Surg 1997;5:457-8.
13. Veith FT, Amor M, Ohki T, Beebe HG, Bell PRF, Bolia A, et al.
Current status of carotid bifurcation angioplasty and stenting based on
a consensus of opinion leaders. J Vasc Surg 2001;33:S111-6.
14. Paniagua D, Howell M, Strickman N, Velasco J, Dougherty K, Skolkin
M, et al. Outcomes following extracranial carotid artery stenting in
high-risk patients. J Invasive Cardiol 2001;13:375-81.
15. Shawl F, Kadro W, Domanski MJ, Lapetina FL, Iqbal AA, Dougherty
KG, et al. Safety and efficacy of elective carotid artery stenting in
high-risk patients. J Am Coll Cardiol 2000;35:1721-8.
16. Magnadottir HB, Lightdale N, Harbaugh RE. Clinical outcomes for
patients at high risk who underwent carotid endarterectomy with re-
gional anesthesia. Neurosurgery 1999;45:786-91.
17. Roubin GS, Gishel N, Sriram I, Jiri V, Nadim A, Ming L, et al.
Immediate and late clinical outcomes of carotid artery stenting in
patients with symptomatic and asymptomatic carotid artery stenosis: a
5-year prospective analysis. Circulation 2001;103:532-7.
18. Perler BA, Dardik A, Burleyson GP, Gordon TA, Williams MG. Influ-
ence of age and hospital volume on the results of carotid endarterec-
tomy: a statewide analysis on 9918 cases. J Vasc Surg 1998;27:25-33.
19. Qureshi AI, Luft AR, Lopes DK, Lanzino G, Fessler RD, Sharma M, et
al. Postoperative hypotension after carotid angioplasty and stenting:
report of three cases. Neurosurgery 1999;44:1320-4.
20. Agmon Y, Khandheria BK, Meissner I, Schwartz GL, Petterson TM,
O’Fallon WM, et al. Relation of coronary artery disease and cerebrovas-
cular disease with atherosclerosis of the thoracic aorta in the general
population. Am J Cardiol 2002;89:262-7.
21. Furguson GG, Eliasziw M, Barr HWK, Clagett GP, Barnes RW, Wal-
lace CM, et al. The North American Symptomatic Carotid Endarterec-
tomy Trial: surgical results in 1415 patients. Stroke 1999;30:1751-8.
22. Mattos MA, Barkmeier LD, Hodgson KJ, Ramsey DE, Sumner DS.
Internal carotid artery occlusion: operative risks and long-term stroke
rates after contralateral carotid endarterectomy. Surgery 1992;112:
670-80.
23. Mackey WC, O’Donnell TF Jr, Callow AD. Carotid endarterectomy
contralateral to an occluded carotid artery: perioperative risk and late
results. J Vasc Surg 1990;11:778-85.
24. Hans SS, Shah S, Hans B. Carotid endarterectomy for high plaques.
Am J Surg 1989;157:431-5.
25. Hobson RW, Goldstein J, Jamil Z, Lee B, Padberg F, Pappas P, et al.
Carotid restenosis: operative and endovascular management. J Vasc
Surg 1999;29:228-38.
26. Ricotta JJ, O’Brien MS, DeWeese JA. Natural history of recurrent and
residual stenosis after carotid endarterectomy: implications for postop-
erative surveillance and surgical management. Surgery 1992;112:656-
63.
27. Mattos MA, van Bemmelen PS, Barkmeier LD, Hodgson KJ, Ramesey
DE, Sumner DS. Routine surveillance after carotid endarterectomy:
does it affect clinical management. J Vasc Surg 1993;17:819-31.
JOURNAL OF VASCULAR SURGERY
January 200344 Gasparis et al
28. Das MB, Hertzer NR, Ratliff NB, O’Hara PJ, Beven EG. Recurrent
carotid stenosis: a five-year series of 65 reoperations. Ann Surg 1985;
202:28-35.
29. Piepgras DG, Sundt TM Jr, Marsh WR, Mussman LA, Fode NC.
Recurent carotid stenosis: results and complications of 57 operations.
Ann Surg 1986;203:205-13.
30. Bradley HB, Olcott C, Dalman RL, Harris J, Zarins CK. Reoperation
for carotid stenosis is as safe as primary carotid endarterectomy. J Vasc
Surg 1999;30:26-35.
31. Gagne PJ, Riles TS, Jacobowitz GR, Lamparello PJ, Giangola G,
Adelman MA, et al. Long-term follow-up of patients undergoing
reoperation for recurrent carotid artery disease. J Vasc Surg 1993;18:
991-1001.
32. Kashyap VS, Moore WS, Quinones-Baldrich WJ. Carotid artery repair
for radiation-associated atherosclerosis is a safe and durable procedure.
J Vasc Surg 1999;29:90-9.
33. Friedell ML, Joseph BP, Cohen MJ, Horowitz JD. Surgery for carotid
artery stenosis following neck irradiation. Ann Vasc Surg 2001;15:13-8.
Submitted Jun 18, 2002; accepted Sep 30, 2002.
DISCUSSION
Dr William D. Jordan, Jr (Birmingham, Ala). I thank you
for the presentation. I thought your data were excellent and they
add to literature that has been presented before. I ask you two
questions.
First, we have a lot of information about these high-risk
patients, but the data are mostly presented to the surgeons. How
would you propose we help disseminate this information to our
nonsurgical colleagues, specifically neurologists, family practice
doctors, primary care internists?
Secondly, while we have had some caution in our surgical area
at UAB about stenting, we still do select some patients for stenting.
I would like to know how you decide who should be stented,
rather than undergo open surgery or be maintained on medical
therapy.
Dr John J. Ricotta. I think other than trying to get these
kind of data on the Stroke meetings or at the Heart Association or
get them into publications that our colleagues read, I am not sure
what else we can do. And at least I have not seen a great interest in
this on the part of our cardiology or neurologic colleagues in terms
of acceptance on their programs.
We have stented, I think, between the two institutions, I think
we have had six or eight people that have been stented in that time
period. So, we are fairly restrictive about it.
I think the people that I would stent would be a symptomatic
recurrence or somebody with an asymptomatic recurrence who has
a contralateral occlusion. I am not sure that stenting an asymptom-
atic, particularly an asymptomatic early recurrence, is particularly
helpful because those people have a pretty benign course anyway.
So, a unilateral, early recurrence, I probably would just observe.
One with a contralateral occlusion, I might stent, or a symptomatic
patient that was a recurrence, I might stent, if it was early. If it was
late, I would be inclined to operate on it because those people have
degenerative atheromas. And I think the radiated patients are a
reasonable group to stent, although there are people—George
Andros has written a nice paper—and there are a number of people
that have written papers that have suggested you could operate on
these radiated people safely. You probably can stent them safely,
too. So, those are the two groups.
We had one patient that I sent for a stent who had unstable
angina and already had a coronary, had nonreconstructible disease
and a symptomatic lesion, but that is one person in 5 years.
Dr Takao Ohki (Bronx, NY). First of all, I believe that your
high-risk definition derived from cardiology literature in which the
high risk is ill defined. I think you derived those definitions from
the bogus publication from the cardiology literature. I would like
to make it clear that unlike the cardiology papers that you have
quoted, the industry-sponsored and the NIH-sponsored clinical
trials have a stricter high-risk definition, of which, age 80, which
was part of your high-risk definition and comprises about one third
of your high-risk cohort, is not included in any of those currently
ongoing high-risk clinical registries or trials. So, that is one point I
would like to make. If you take out the age 80, one third of the
patients, the overall flavor or the conclusion might be slightly
different.
My question is, John, I think I have recognized a difference in
tone before you did endograft for AAA and after you do it yourself
now. And I think we will see the same difference in tone once you
start doing carotid stenting. The endpoint you have used in your
study was stroke and death. And I agree that if the endpoint was
stroke and death, there might be little difference, especially if you
include age 80 and other bogus factors. But there are other
endpoints than stroke and death. For example, if you look at length
of stay, the struggle for both the patient and the surgeon, the risk
of cranial nerve injury and so forth, and if there is a better way to
treat those subset of patients that are truly high risk, I think we
should try to embrace the technology and not try to say that there
is no such thing as a high risk.
Dr Ricotta. I think the point of this paper was to try to
indicate that the very broad definitions of high risk that are being
used in the literature by people that do carotid stenting as a
rationale for extending that procedure to large numbers of patients
outside of clinical trials is flawed.
Now, I do not disagree that there is probably a high-risk group
of patients. I think that that goes without saying. But I think that
it is probably only 4% or 5% of the patients that people see in a
normal practice. And it certainly is not consonant with the level of
carotid stenting that we are seeing in the community.
So, I would agree, number one, that we should be doing
prospective randomized trials. And if you have the equipoise to
send an asymptomatic patient to a prospective randomized trial, I
think that you should do that. And I have no problem with that.
And I have no problem, certainly, with the CREST trial. But I
think that what is happening is there are a lot of patients that are
having carotid stents based on the rationale that they are in a
high-risk subgroup, and they really are not in a high-risk subgroup.
Those patients can be offered surgery very well and very easily.
Once it is demonstrated that this technology is efficacious, I
think that it should and would be embraced. The difference
between a carotid endarterectomy and an open aneurysm and a
stentgraft versus a carotid endarterectomy and a carotid stent is a
very different kettle of fish.
Dr Frank W. LoGerfo (Boston, Mass). I do just have one
quick comment related to this and that is to keep in mind that we
are talking here about the potential of 100,000 stents at roughly
$4000 apiece. That is a $400 million force that is behind the scenes
here. So, it is easy to suddenly decide that you have some high-risk
patients because of the ways in which that can work to coerce you.
The bottom line is this operation works extremely well, it is
extremely safe for our patients. And when we say we have patients
who are too high risk for surgery, we tell the world that surgery is
risky and we take away from our patients a very safe procedure. So,
think carefully about your involvement in these studies. I have no
problem with prospective randomized trials, that is exactly what we
should do.
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Dr Ali AbuRahma (Charleston, WV). One of the most
commonly quoted problems with cardiologists regarding carotid
endarterectomy is the incidence of cranial nerve injury. Did you
look into this subset of patients who had redo surgery, high cervical
lesions, or neck radiation to see if any of these patients had a higher
incidence of cranial nerve injury that would justify carotid stenting?
Dr Ricotta. We did not look at that subset in terms of cranial
nerve injury. That would be, in my mind, the reason to do those
patients with a stent.
Dr Michael S. Conte (Boston, Mass). We recently looked at
our own results in our division with very similar findings as you
have. The only question I would ask is whether you looked at
long-term outcomes in the high-risk patients? We have noticed
some difference in long-term survival in the cohort with multiple
comorbidities, which does not necessarily bear on which procedure
you choose, but whether or not one should do anything at all in
some of these asymptomatic patients with multiple high-risk fac-
tors. So, did you look at the long-term survival or long-term
stroke-free survival?
Dr Ricotta. Looking at the long-term stroke-free survival
was not part of this study, but I would agree with you, Mike, that
asymptomatic patients need to be able to survive for a certain
period of time to achieve a benefit. At the same time, once they
survive the surgery, they immediately achieve that benefit. And my
experience with elderly patients is that sometimes they would
rather die than have a stroke and do push us to do surgery
sometimes.
Dr Peter R. F. Bell (Leicester, United Kingdom). I agree
with your conclusions. We, in fact, published a paper a few years
ago that showed that the over 80 do just as well as those under 80.
And secondly, the high-risk patients who cannot take anesthe-
sia can have local anesthesia if necessary. You did not mention that.
Did any of your patients have local anesthesia?
Dr Ricotta. My preference is to do the high-risk patients with
local anesthesia. But this was a group, I think there were five or six
surgeons in the group, and I think I am in the minority. But that is
my preference.
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